Comorbidities in unclassifiable interstitial lung disease.
Cluster analyses
Comorbidities
Disease course
Mortality
Unclassifiable interstitial lung disease
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
16 Mar 2022
16 Mar 2022
Historique:
received:
24
09
2021
accepted:
08
03
2022
entrez:
17
3
2022
pubmed:
18
3
2022
medline:
25
3
2022
Statut:
epublish
Résumé
Comorbidities are common in interstitial lung diseases (ILD) and have an important association with survival, but the frequency and prognostic impact of comorbidities in unclassifiable interstitial lung disease (uILD) remains elusive. We aimed to describe the prevalence of comorbidities and assess the impact on survival in patients with uILD. Furthermore, we aimed to identify and characterize potential phenotypes based on clusters of comorbidities and examine their association with disease progression and survival. Incident patients diagnosed with uILD were identified at two ILD referral centers in Denmark and Germany from 2003 to 2018. The diagnosis uILD was based on multidisciplinary team meetings. Clinical characteristics and comorbidities were extracted from ILD registries and patient case files. Survival analyses were performed using Cox regression analyses, disease progression was analyzed by linear mixed effects models, and clusters of comorbidities were analyzed using self-organizing maps. A total of 249 patients with uILD were identified. The cohort was dominated by males (60%), former (49%) or current (15%) smokers, median age was 70 years, mean FVC was 75.9% predicted, and mean DLCO was 49.9% predicted. One-year survival was 89% and three-year survival was 73%. Eighty-five percent of the patients had ≥ 1 comorbidities, 33% had ≥ 3 comorbidities and 9% had ≥ 5 comorbidities. The only comorbidity associated with excess mortality was dyslipidemia. No association between survival and number of comorbidities or the Charlson comorbidity index was observed. Three clusters with different comorbidities profiles and clinical characteristics were identified. A significant annual decline in FVC and DLCO % predicted was observed in cluster 1 and 2, but not in cluster 3. No difference in mortality was observed between the clusters. The comorbidity burden in uILD is lower than reported in other types of ILD and the impact of comorbidities on mortality needs further clarification. Three clusters with distinct comorbidity profiles were identified and could represent specific phenotypes. No difference in mortality was observed between clusters, but slower disease progression was observed in cluster 3. Better understanding of disease behavior and mortality will require further studies of subgroups of uILD with longer observation time.
Sections du résumé
BACKGROUND
BACKGROUND
Comorbidities are common in interstitial lung diseases (ILD) and have an important association with survival, but the frequency and prognostic impact of comorbidities in unclassifiable interstitial lung disease (uILD) remains elusive. We aimed to describe the prevalence of comorbidities and assess the impact on survival in patients with uILD. Furthermore, we aimed to identify and characterize potential phenotypes based on clusters of comorbidities and examine their association with disease progression and survival.
METHODS
METHODS
Incident patients diagnosed with uILD were identified at two ILD referral centers in Denmark and Germany from 2003 to 2018. The diagnosis uILD was based on multidisciplinary team meetings. Clinical characteristics and comorbidities were extracted from ILD registries and patient case files. Survival analyses were performed using Cox regression analyses, disease progression was analyzed by linear mixed effects models, and clusters of comorbidities were analyzed using self-organizing maps.
RESULTS
RESULTS
A total of 249 patients with uILD were identified. The cohort was dominated by males (60%), former (49%) or current (15%) smokers, median age was 70 years, mean FVC was 75.9% predicted, and mean DLCO was 49.9% predicted. One-year survival was 89% and three-year survival was 73%. Eighty-five percent of the patients had ≥ 1 comorbidities, 33% had ≥ 3 comorbidities and 9% had ≥ 5 comorbidities. The only comorbidity associated with excess mortality was dyslipidemia. No association between survival and number of comorbidities or the Charlson comorbidity index was observed. Three clusters with different comorbidities profiles and clinical characteristics were identified. A significant annual decline in FVC and DLCO % predicted was observed in cluster 1 and 2, but not in cluster 3. No difference in mortality was observed between the clusters.
CONCLUSIONS
CONCLUSIONS
The comorbidity burden in uILD is lower than reported in other types of ILD and the impact of comorbidities on mortality needs further clarification. Three clusters with distinct comorbidity profiles were identified and could represent specific phenotypes. No difference in mortality was observed between clusters, but slower disease progression was observed in cluster 3. Better understanding of disease behavior and mortality will require further studies of subgroups of uILD with longer observation time.
Identifiants
pubmed: 35296320
doi: 10.1186/s12931-022-01981-3
pii: 10.1186/s12931-022-01981-3
pmc: PMC8925215
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
59Informations de copyright
© 2022. The Author(s).
Références
Semin Respir Crit Care Med. 2020 Apr;41(2):177-183
pubmed: 32279289
Respir Res. 2021 Apr 26;22(1):125
pubmed: 33902584
Respir Res. 2020 Jan 9;21(1):12
pubmed: 31918716
Respir Med. 2004 Jun;98(6):567-73
pubmed: 15191043
Respirology. 2018 Jun;23(6):606-612
pubmed: 29251396
Respir Med. 2021 Aug-Sep;185:106490
pubmed: 34130097
Nat Rev Drug Discov. 2005 Dec;4(12):977-87
pubmed: 16341063
Respirology. 2017 Apr;22(3):494-500
pubmed: 28297158
Respir Med. 2014 Apr;108(4):647-53
pubmed: 24529739
Respir Med. 2014 May;108(5):793-9
pubmed: 24636811
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
PLoS One. 2016 Mar 29;11(3):e0151425
pubmed: 27023440
J Med Econ. 2012;15(5):829-35
pubmed: 22455577
Pneumologie. 2018 Jun;72(6):446-457
pubmed: 29466814
Eur Respir J. 2015 Oct;46(4):1113-30
pubmed: 26424523
J Clin Med. 2020 Aug 03;9(8):
pubmed: 32756496
Respiration. 2018;96(1):29-40
pubmed: 29874679
J Korean Med Sci. 2012 Jul;27(7):756-60
pubmed: 22787370
Arch Public Health. 2021 Mar 24;79(1):40
pubmed: 33762017
Lancet Respir Med. 2020 Feb;8(2):147-157
pubmed: 31578169
Am J Respir Cell Mol Biol. 2005 Apr;32(4):290-300
pubmed: 15677772
Life Sci. 2013 Dec 18;93(25-26):968-74
pubmed: 24211780
Lancet Respir Med. 2016 May;4(5):381-9
pubmed: 27050871
Circulation. 2003 Jul 29;108(4):426-31
pubmed: 12860913
Eur Respir J. 2013 Sep;42(3):750-7
pubmed: 23222877
Lancet Respir Med. 2013 Jul;1(5):369-76
pubmed: 24429201
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307